Evaluation of the Prevalence of Hepatitis B and C in Patients with Lymphoma

Aim:Hepatitis enfection reactivation during chemotherapy is a major problem in lymphoma patients. We aimed to investigate the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in lymphoma patients treated in our center.Materials and Methods:The files of non-hodgkin lymphoma (NHL) and hodgkin lymphoma (HL) patients treated in our center between 2011-2018 were retrospectively reviewed. HBsAg, Anti-HBs, Anti-HBc and Anti-HCV parameters of the patients were evaluated.Results:In 21 (8.7%) of the 240 NHL patients, HBsAg antigen was positive. Anti-HCV positivity was detected in 9 patients (3.7%). In 79 (33%) patients, HBsAg (-), Anti-HBs (+) and Anti-HBc (+) were detected and evaluated as previous hepatitis B infection. In 10 (9.1%) of the 110 HL patients, HBsAg was positive and Anti-HCV positivity was detected in 3 patients (2.7%). In 29 (26.4%) patients, HBsAg (-), Anti-HBs (+) and Anti-HBc (+) were detected and evaluated as previous hepatitis B infection. When HBsAg and Anti-HCV positivity rates were compared between NHL and HL patient groups, no statistically significant difference was detected (p values were 0.9 and 0.63, respectively).Conclusion:According to the data of our country higher positivity of HBV and HCV was determined in lymphoma patients. Hepatitis B and C positivity in our region poses an important problem. Necessary information about vaccination and prevention methods should be provided

The Correlation between biochemical bone markers, bone dansitometry and iron accumulationn in patients with thalassemia major, intermedia and sickle cell disease.

TEZ10661Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 2015.Kaynakça (s. 68-79) var.ix, 80 s. : res. (bzs. rnk.), tablo ; 29 cm.Amaç: Çalışmanın amacı Ç.Ü.T.F Hematoloji polikliniğinde takip edilen talasemi major, intermedia ve orak hücre hastalarında biyokimyasal kemik belirteçleri ve kemik dansitometrisi arasındaki ilişkinin belirlenmesidir. Gereç ve Yöntem: Bu çalışmada Ç.Ü.T.F hematoloji polikliniğinde takip edilen 102 talasemi major, intermedia ve orak hücre hastası prospektif olarak incelenmiştir. Hastalardan biyokimyasal kemik belirteçleri olarak kalsiyum, fosfor, alkalen fosfataz, D vitamini,parathormon ve ferritin bakıldı.Çekilen kemik dansitometrileri ile ilişkiler karşılaştırıldı.Verilerin değerlendirilmesinde SPSS 20.0 (SPSS Inc.Chicago, III, USA) paket programı kullanıldı. Bulgular: Osteoporoz hemoglobinopatisi olan hastalarda normal populasyona göre oldukça sık bulunmuştur. Talasemi major, intermedia ve orak hücre hastalarında D vitamini düzeyleri oldukça düşük bulunmuştur. D vitamini düşüklüğü ve ferritin yüksekliği DEXA skorlarındaki gerileme ile istatiksel olarak anlamlı bulunmuştur. Özellikle ağır D vitamini eksikliğinde DEXA skorlarındaki gerileme daha barizdir. Sonuç: Talasemi major, intermedia ve orak hücre hastalarının erken yaşlarda kemik dansitometrisi ile taramaları yapılmalı, kemik parametreleri incelenmelidir. Uygun D vitamini replasmanı ve ferritin düzeylerinin normal aralığa çekilmeye çalışılması osteporoza bağlı morbiditeyi azaltacaktır.Objective: The purpose of this study, to determine the relationship between bone dansitometry and biochemical bone markers in thallasemia major, intermedia and sickle cell anemia patients who have been followed by C.U.T.F Hematology Clinic Materials and methods: We studied prospectively 102 thallasemia major, intermedia and sickle cell anemia patients who have been followed by C.U.T.F Hematology Clinic, in this study. As a biochemical bone marker we tested calcium , phosphorus , alcalene phosphatase ,parathormon ,ferritin and D vitamine values. This biochemical bone marker values were compared with bone dansitometry results. SPSS 20.0( SPSS Inc. Chicago,III, USA) packet programme was used for evaluating the results. Findings: Osteoporosis was found frequently at patients who have hemoglobinopathy. Also D vitamine values were obtained significantly lower levels at patients. It is significantly obtained that there is a relationship between low vitamin D, high ferritin levels and DEXA score decreasing. Especially, severe D vitamine deficincy with DEXA score decreasing is more evident. Result: Researching with bone dansitometry and biochemical bone markers at younger ages is important between thallasemia major, intermedia and sickle cell anemia patients. Replacing sufficient D vitamine and maintaining ferritin levels to normal range will reduce the morbidity of osteoporosis

Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactive Iodine: A Case Report

Background: Thyroid cancer is the most common endocrine cancer, with an increasing incidence around the world in the last three decades. The increased risk of secondary cancer is associated with a genetic predisposition or radioactive iodine used in the treatment. Case Report: A 65-year old male patient was operated on for thyroid papillary cancer. He received radioactive iodine on two occasions postoperatively. After six years, he presented with malaise and fatigue with leukocytosis and eosinophlilia. The physical examination revealed inguinal lymphadenopathies and splenomegaly, after examining the bone marrow and lymph node biopsies, he was diagnosed with eosinophilic myeloproliferative neoplasia and T-cell lymphoblastic leukaemia/lymphoma. Conclusion: Leukaemia and other haematological malignencies may develop after radioactive iodine treatment. Patients with radioactive iodine ablation history should be monitored for a long time

Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactive Iodine: A Case Report

Background: Thyroid cancer is the most common endocrine cancer, with an increasing incidence around the world in the last three decades. The increased risk of secondary cancer is associated with a genetic predisposition or radioactive iodine used in the treatment. Case Report: A 65-year old male patient was operated on for thyroid papillary cancer. He received radioactive iodine on two occasions postoperatively. After six years, he presented with malaise and fatigue with leukocytosis and eosinophlilia. The physical examination revealed inguinal lymphadenopathies and splenomegaly, after examining the bone marrow and lymph node biopsies, he was diagnosed with eosinophilic myeloproliferative neoplasia and T-cell lymphoblastic leukaemia/lymphoma. Conclusion: Leukaemia and other haematological malignencies may develop after radioactive iodine treatment. Patients with radioactive iodine ablation history should be monitored for a long time.Background: Thyroid cancer is the most common endocrine cancer, with an increasing incidence around the world in the last three decades. The increased risk of secondary cancer is associated with a genetic predisposition or radioactive iodine used in the treatment. Case Report: A 65-year old male patient was operated on for thyroid papillary cancer. He received radioactive iodine on two occasions postoperatively. After six years, he presented with malaise and fatigue with leukocytosis and eosinophlilia. The physical examination revealed inguinal lymphadenopathies and splenomegaly, after examining the bone marrow and lymph node biopsies, he was diagnosed with eosinophilic myeloproliferative neoplasia and T-cell lymphoblastic leukaemia/lymphoma. Conclusion: Leukaemia and other haematological malignencies may develop after radioactive iodine treatment. Patients with radioactive iodine ablation history should be monitored for a long time

Merkel cell carcinoma in Turkey: A multicentric study

Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Aim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC